GlassScriptPhysician profile
Da Hea Kim
NPI 1487017851
$2,146.27
in general payments reported to CMS, 2019-2025
27 companies · $518 in 2025
The $518 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $444 · 2023: $467 · 2024: $287 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $333.61 | 2021-2025 | Nexplanon, Nuvaring |
| Bayer Healthcare Pharmaceuticals INC. | $214.46 | 2021-2025 | |
| Abbvie INC. | $175.20 | 2021-2023 | |
| Coopersurgical, INC. | $159.59 | 2021-2025 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Sage Therapeutics, LLC | $140.47 | 2022-2025 | Zurzuvae |
| Pfizer INC. | $135.79 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $133.89 | 2022-2025 | |
| Astellas Pharma US INC | $130.57 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $105.25 | 2023-2024 | Accrufer |
| Exeltis, USA INC. | $101.63 | 2021-2022 | |
| Biogen, INC. | $89.54 | 2025 | Zurzuvae |
| Gynesonics, INC. | $65.92 | 2021 | |
| Molnlycke Health Care US, LLC | $53.60 | 2021 | |
| Avion Pharmaceuticals | $50.78 | 2021-2023 | Balcoltra |
| Ethicon US, LLC | $42.92 | 2023 | Ethicon, Stratafix, Enseal |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $23.65 | 2022 | |
| Dexcom, INC. | $23.33 | 2025 | Dexcom G6 Transmitter |
| Renovia INC | $20.86 | 2021 | |
| Dynavax Technologies Corporation | $19.19 | 2025 | Heplisav-B |
| Aspira Women'S Health INC | $19.18 | 2023 | Ova1 |
| Millicent US INC | $18.48 | 2025 | Femlyv |
| Merck Sharp & Dohme LLC | $17.20 | 2021 | |
| Meditrina | $15.90 | 2024 | |
| Supernus Pharmaceuticals, INC. | $14.27 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $13.89 | 2022 | |
| Optumhealth Care Solutions, LLC | $13.70 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Minerva Surgical, INC | $13.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da Hea Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.